Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,765 total articles
Diana Shipping Inc., a public US-listed dry bulk shipping company, has launched www.CashforGenco.com to support its campaign to elect six independent directors to Genco Shipping & Trading's board. Diana owns approximately 14.7% of Genco and has made an all-cash acquisition offer of $23.50 per share, representing a 31% premium. Diana highlights alle…
ZenaTech announces the establishment of Phoenix Aero LLC in Lviv, Ukraine, as a manufacturing hub for AI-enabled counter-UAS and interceptor drones aimed at Gulf Cooperation Council defense customers. The initiative leverages cost-effective production and real-world testing to meet growing Middle Eastern demand for scalable, affordable defense dron…
MiNK Therapeutics announced clinical data demonstrating that its off-the-shelf, allogeneic iNKT cell therapy, agenT-797, triggers disease-appropriate immune responses without genetic modification. The same cell product activated pro-inflammatory responses in cancer patients and anti-inflammatory effects in ARDS patients from the same manufacturing …
Collegium Pharmaceutical has finalized its acquisition of AZSTARYS, an ADHD medication, from Corium Therapeutics for approximately $650 million. The acquisition expands Collegium's ADHD product portfolio, leveraging existing commercial infrastructure to accelerate growth. The company has raised its 2026 financial guidance, expecting product revenue…
Mereo BioPharma disclosed its first quarter 2026 financial results and corporate updates, emphasizing ongoing regulatory discussions regarding setrusumab's potential pediatric use, active partnership talks for alvelestat Phase 3 development, and advancement of vantictumab's Phase 2 trial. Despite not meeting primary endpoints in setrusumab Phase 3 …
TappAlpha has announced surpassing $500 million in assets under management, doubling within just four months. The company's Growth + Income ETF strategies, including TSPY and TDAQ, focus on combining growth exposure with a tax-efficient income overlay. This milestone reflects strong advisor and investor demand for strategies that generate income wi…
Xilio Therapeutics reported strong first-quarter 2026 financial and operational results. The company is on track to submit an IND for XTX501, a bispecific PD-1/masked IL-2 therapy, mid-2026, with Phase 1 trial initiation planned for the second half of 2026. It presented promising preclinical data for XTX601 targeting CLDN18.2 and advanced multi-spe…
BriaCell Therapeutics Corp. reports that over 230 patients have been enrolled in its pivotal Phase 3 Bria-ABC study testing Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer. The study, which has FDA Fast Track designation, expects to report interim topline overall survival data in 2026, potentially supporting…
Harvard Bioscience announced its financial results for Q1 2026, achieving revenues of $20.8 million with a gross margin improvement to 59%. The company remains profitable on an adjusted EBITDA basis and is progressing on manufacturing consolidation to achieve cost efficiencies. Adoption of higher-margin new product innovations (NPI), such as the Me…
Aveanna Healthcare Holdings Inc. announced its participation and presentation at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. The company will showcase its range of pediatric and adult healthcare services, highlighting its focus on providing high-quality, cost-effective care alternatives to prolonged hospitalization.
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in two major investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 Stifel Virtual Targeted Oncology Forum. The company will provide webcast presentations and offer one-on-one meetings for i…
SAB Biotherapeutics announced Q1 2026 financial results and highlighted ongoing enrollment in their registrational Phase 2b SAFEGUARD trial of SAB-142 for type 1 diabetes. The company reported encouraging Phase 1 data showing C-peptide preservation and better glycemic control, secured $95 million from a public offering to fund operations through 20…
Sagimet Biosciences reported strong first quarter 2026 financial results, highlighted by securing $175 million in equity financing to fund operations through 2028. The company announced plans to initiate a Phase 3 clinical trial of its novel acne drug denifanstat in the U.S. in the second half of 2026, targeting moderate to severe acne. Ongoing Pha…
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). The Phase 3 CALIBRATE trial met all primary and key secondary endpoints, demonstrating rapid and durable improvements in calcium regulation and a favorable safety profile. Encaleret may receiv…
Zevra Therapeutics, a commercial-stage biopharmaceutical company focused on rare diseases, announced its executive team will present at the H.C. Wainwright BioConnect Investor Conference to discuss the company's progress and strategic outlook. The presentation underscores Zevra's commitment to advancing its pipeline and broadening patient access to…
Nayax Ltd. announced robust financial results for Q1 2026, reporting a 32% increase in revenue to $106.9 million, organic revenue growth of 26%, and a 43% year-over-year increase in adjusted EBITDA to $13.9 million. The company expanded its installed base to over 1.5 million devices and customer base to 120,000, demonstrating successful scale and r…
TransUnion's latest report reveals that the median age of renters has risen to 40, with many delaying or foregoing homeownership due to economic factors. This demographic shift presents a strategic growth opportunity for insurers, as these renters demonstrate stable incomes, strong credit profiles, and increasing demand for comprehensive insurance …
POET Technologies Inc., a Nasdaq-listed company specializing in integrated optical engines and light sources for AI networks, announced the appointment of Sandeep Kumar as Chief Operating Officer. Dr. Kumar brings extensive semiconductor operations experience from Silicon Labs and other industry leaders. His immediate focus will be on preparing POE…
Hub Group, Inc. has filed a Notification of Late Filing for its quarterly report and disclosed delays in its annual report due to identified accounting inaccuracies requiring restatement of financials for 2023, 2024, and part of 2025. Despite operational growth in intermodal and logistics, brokerage volume declined as the company focuses on profita…
Arvinas, Inc. announced FDA approval of VEPPANU™ (vepdegestrant), the first PROTAC therapy approved for treating ESR1-mutated, ER+/HER2- advanced breast cancer, marking a milestone for the company and the PROTAC modality. The company reported strong clinical progress in its pipeline including positive Phase 1 data for ARV-102 in Parkinson’s disease…
Achieve Life Sciences announced key senior appointments to its board and commercial team, including executives from Verona Pharma, signaling a strong push towards commercializing cytisinicline, a novel treatment for nicotine dependence with FDA review anticipated in June 2026. These leadership additions come shortly after a substantial $354 million…
NeurAxis, Inc. reported a record first quarter for 2026 with revenues up 80% year-over-year to $1.6 million driven by the implementation of the Category I CPT code for their IB-Stim device. The company expanded gross margin and reduced operating losses while securing significant regulatory and commercial milestones including Veterans Affairs contra…
Unicycive Therapeutics announced its first quarter 2026 financial results alongside an optimistic update on the FDA review process for oxylanthanum carbonate (OLC), a novel phosphate binder targeting hyperphosphatemia in chronic kidney disease dialysis patients. The company highlighted its preparedness for a potential product launch following a Jun…
CorVel Corporation will host a live webcast on May 20, 2026, to discuss its quarterly and fiscal earnings, featuring its CEO and CFO. The webcast will include insights into financial performance, strategic initiatives, and a Q&A session. The company highlights its focus on technology-driven risk management solutions in healthcare-related sectors.
Prelude Therapeutics reported Q1 2026 financial results highlighting progress in its oncology pipeline including initiation of a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor, advancement of PRT13722, a selective oral KAT6A degrader for ER+ breast cancer, and development of novel degrader antibody conjugates. The company extend…
